A142 INFLAMMATORY BOWEL DISEASE PATIENTS REQUIRE AN INCREASED ADALIMUMAB DRUG LEVEL TO SIMULTANEOUSLY ACHIEVE CLINICAL AND BIOLOGICAL REMISSION

BACKGROUND: Physicians use therapeutic drug monitoring of adalimumab (ADA) as an optimization tool to guide patient therapy with inflammatory bowel disease (IBD). IBD consists primarily of Crohn’s disease (CD) and ulcerative colitis (UC). Presently, the literature on ADA therapeutic boundaries recom...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Can Assoc Gastroenterol
Main Authors: Cookson, T A, Stern, N C, Sutton, R T, Fedorak, R, Halloran, B, Dieleman, L A, Wong, K, Huang, V, Peerani, F, van Zanten, S, Lazarescu, A, Kroeker, K
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Posters Of Distinction
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6512604/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwz006.141
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados